Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective s...
Main Authors: | Lucia Brescini, Filippo Della Martera, Gianluca Morroni, Sara Mazzanti, Maria Di Pietrantonio, Paolo Mantini, Bianca Candelaresi, Francesco Pallotta, Silvia Olivieri, Valentina Iencinella, Sefora Castelletti, Emanuele Cocci, Rosaria G. Polo, Salvatore Veccia, Oscar Cirioni, Marcello Tavio, Andrea Giacometti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/10/9/1129 |
Similar Items
-
Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study
by: Laura Morata Ruiz, et al.
Published: (2024-03-01) -
Multidisciplinary panel opinion on the management of bacterial skin infections
by: Emilio Bouza, et al.
Published: (2022-09-01) -
A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice
by: Frank Hanses, et al.
Published: (2022-04-01) -
Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
by: Anna Lange, et al.
Published: (2023-10-01) -
The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
by: Elisa Molinelli, et al.
Published: (2022-11-01)